Effect of age on the prognosis of intrahepatic cholangiocarcinoma
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Intrahepatic cholangiocarcinoma (iCCA) is a subgroup of cholangiocarcinoma and is the second- most-common primary hepatic tumor. Several predictive and prognostic factors have been analyzed; however, in this study we focused on the influence of age. Our aim was to use real-world results to determine the influence of age in iCCA patients. Methods: A retrospective analysis of patients treated between 2005 and 2016 at Konkuk University Medical Center. In total, 133 patients with iCCA were identified. The mass-forming, periductal-infiltrating, and intraductal-growth types were included; patients with extrahepatic or hilar-type cholangiocarcinoma were excluded. We defined two groups: a younger group, age < 65 years, and an older group, age ≥ 65 years. Statistical analyses using univariate and multivariate Cox regression analyses, including the Kaplan-Meier method, were conducted. Results: In total, 114 patients were enrolled. The two groups differed with regard to treatment options such as surgery with adjuvant chemotherapy or palliative chemotherapy (p = 0.012, p < 0.001). The younger group had significantly longer survival than the older group (p = 0.017). In the younger group, patients who received therapy had longer survival than those who did not (hazard ratio, 3.942; 95% confidence interval, 2.053 to 7.569; p < 0.001). Multivariate analysis indicated that younger age, lower bilirubin, low CA 19-9, and no lymph-node involvement were independent factors for improved survival. Conclusions: Younger patients and those who underwent surgery with adjuvant chemotherapy had longer survival. The younger the patient, the more treatments received, including palliative chemotherapy.
Abstract
Background/Aims: Intrahepatic cholangiocarcinoma (iCCA) is a subgroup of cholangiocarcinoma and is the second- most-common primary hepatic tumor. Several predictive and prognostic factors have been analyzed; however, in this study we focused on the influence of age. Our aim was to use real-world results to determine the influence of age in iCCA patients. Methods: A retrospective analysis of patients treated between 2005 and 2016 at Konkuk University Medical Center. In total, 133 patients with iCCA were identified. The mass-forming, periductal-infiltrating, and intraductal-growth types were included; patients with extrahepatic or hilar-type cholangiocarcinoma were excluded. We defined two groups: a younger group, age < 65 years, and an older group, age ≥ 65 years. Statistical analyses using univariate and multivariate Cox regression analyses, including the Kaplan-Meier method, were conducted. Results: In total, 114 patients were enrolled. The two groups differed with regard to treatment options such as surgery with adjuvant chemotherapy or palliative chemotherapy (p = 0.012, p < 0.001). The younger group had significantly longer survival than the older group (p = 0.017). In the younger group, patients who received therapy had longer survival than those who did not (hazard ratio, 3.942; 95% confidence interval, 2.053 to 7.569; p < 0.001). Multivariate analysis indicated that younger age, lower bilirubin, low CA 19-9, and no lymph-node involvement were independent factors for improved survival. Conclusions: Younger patients and those who underwent surgery with adjuvant chemotherapy had longer survival. The younger the patient, the more treatments received, including palliative chemotherapy.
참고문헌 (25)
- Massarweh NN, "Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma", Cancer Control, 24, pp.1073274817729245~ (2017)
- Antwi SO, "Racial, ethnic, and age disparities in incidence and survival of intrahepatic cholangiocarcinoma in the United States; 1995-2014", Ann Hepatol, 17, pp.604~614 (2018)
- El-Diwany R, "Intrahepatic cholangiocarcinoma", Surg Oncol Clin N Am, 28, pp.587~599 (2019)
- Matsumoto K, "Hepatitis B and C virus infection is a risk factor for the development of cholangiocarcinoma", Intern Med, 53, pp.651~654 (2014)
- Jung Woong Seo, "Prognostic impact of hepatitis B or C on intrahepatic cholangiocarcinoma", The Korean Journal of Internal Medicine, 35(3), pp.566~573 (2020), 대한내과학회[DOI]
- Hughes N, "The management of adolescents and young adults with cancer", Cancer Treat Rev, 67, pp.45~53 (2018)
- Zhao L, "Poor prognosis of young patients with colorectal cancer : a retrospective study", Int J Colorectal Dis, 32, pp.1147~1156 (2017)
- 정모아, "조기발병 대장암", 대한소화기학회지, 74(1), pp.4~10 (2019), 대한소화기학회[DOI]
- Cheng L, "Gastric cancer in young patients : a separate entity with aggressive features and poor prognosis", J Cancer Res Clin Oncol, 146, pp.2937~2947 (2020)
- Feng H, "Genomic features and clinical characteristics of adolescents and young adults with cholangiocarcinoma", Front Oncol, 9, pp.1439~ (2020)
- de Jong MC, "Intrahepatic cholangiocarcinoma : an international multi-institutional analysis of prognostic factors and lymph node assessment", J Clin Oncol, 29, pp.3140~3145 (2011)
- Nathan H, "Trends in survival after surgery for cholangiocarcinoma : a 30-year population-based SEER database analysis", J Gastrointest Surg, 11, pp.1488~1496 (2007)
- Endo I, "Intrahepatic cholangiocarcinoma : rising frequency, improved survival, and determinants of outcome after resection", Ann Surg, 248, pp.84~96 (2008)
- Reames BN, "Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma:a multi-institutional analysis", HPB(Oxford), 19, pp.901~909 (2017)
- Shroff RT, "Adjuvant therapy for resected biliary tract cancer : ASCO Clinical Practice Guideline", J Clin Oncol, 37, pp.1015~1027 (2019)
- Kelley RK, "Systemic therapies for intrahepatic cholangiocarcinoma", J Hepatol, 72, pp.353~363 (2020)
- Le DT, "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade", Science, 357, pp.409~413 (2017)
- Doebele RC, "Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours : integrated analysis of three phase 1-2 trials", Lancet Oncol, 21, pp.271~282 (2020)
- Valle J, "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer", N Engl J Med, 362, pp.1273~1281 (2010)
- Okusaka T, "Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan", Br J Cancer, 103, pp.469~474 (2010)
- Hanazaki K, "Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection : univariate and multivariate analysis", Hepatogastroenterology, 49, pp.311~316 (2002)
- Wu RY, "Evaluation and recommendation of the 8th edition of American Joint Committee on Cancer(AJCC)staging system for intrahepatic cholangiocarcinoma(ICC)in 820 patients from the Surveillance, Epidemiology, and End Results(SEER)database", J Gastrointest Surg, 25, pp.145~154 (2021)
- Koch C, "Poor prognosis of advanced cholangiocarcinoma : real-world data from a tertiary referral center", Digestion, 101, pp.458~465 (2020)
- Gurlevik E, "Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma", Hepatology, 58, pp.1031~1041 (2013)
- Matsuda T, "Preoperative prognostic nutritional index predicts postoperative infectious complications and oncological outcomes after hepatectomy in intrahepatic cholangiocarcinoma", BMC Cancer, 21, pp.708~ (2021)